CanSinoBIO: From Profit Turnaround to Value Realization as an Innovative Vaccine Leader
HONG KONG, Mar 31, 2026 – (ACN Newswire via SeaPRwire.com) – China’s 2026 Report on the Work of the Government identified biopharmaceuticals as an emerging pillar industry, underscoring a supportive policy environment for innovative drugmakers. In this context, CanSino Biologics Inc. (688185.SH/06185.HK) has released its Annual Results For The Year 2025, marking a return to profitability […]